Indumathi Chandrasekaran, Anusha Natarajan, Vinod Kolar Vishwanath, Santhosh Satheesh, Dkhar Steven Aibor
PhD Scholar, Department of Pharmacology, JIPMER, Puducherry, India.
Senior Resident, Department of Pharmacology, JIPMER, Puducherry, India.
J Clin Diagn Res. 2017 Jul;11(7):FC01-FC05. doi: 10.7860/JCDR/2017/27223.10175. Epub 2017 Jul 1.
Atorvastatin is the most widely used statin world-over. Although atorvastatin is beneficial in reducing cardiovascular morbidity and mortality, they are associated with Adverse Drug Reactions (ADRs) which are under-recognized as well as under-reported. There is no data on safety of atorvastatin in ethnic populations like South Indian Tamils and hence the need for this study.
To report the Adverse Events (AEs) associated with atorvastatin use, their causality and severity in dyslipidemic south Indian Tamils.
This cross-sectional study was carried out on 304 dyslipidemic Tamils. Those on any lipid lowering therapy within one month before study enrolment, those with contraindications to statin therapy, hypothyroid patients, those with LDL cholesterol >250 mg/dL or serum triglycerides >400 mg/dL and patients who were on drugs which modulate Cytochrome P 450 3A4/5 (CYP3A4/5) activity were excluded from the study. Causality assessment for atorvastatin induced AEs were done using Naranjo adverse drug reaction probability scale criteria and severity assessment was done using Hartwig scale. AEs which were causally related to atorvastatin use were reported as ADRs.
One hundred and eighty three AEs were noted among 145 (47.7%) patients, during the course of first 45 days of atorvastatin therapy. AEs were probably due to atorvastatin in 11% of the patients and possibly due to atorvastatin in 89%. Most common ADRs were myalgia (41%), followed by nervous system ADRs (35.5%) and gastrointestinal ADRs (14%).
Myalgia was the most common cause for atorvastatin discontinuation which might place these individuals at an increased risk of cardiovascular morbidity and mortality. Measures to identify and address atorvastatin induced myalgia should be given priority.
阿托伐他汀是全球使用最广泛的他汀类药物。尽管阿托伐他汀在降低心血管发病率和死亡率方面有益,但它们与药物不良反应(ADR)相关,这些不良反应未得到充分认识和报告。在南印度泰米尔人等种族人群中,没有关于阿托伐他汀安全性的数据,因此需要进行这项研究。
报告血脂异常的南印度泰米尔人使用阿托伐他汀相关的不良事件(AE)、其因果关系和严重程度。
对304名血脂异常的泰米尔人进行了这项横断面研究。在研究入组前一个月内接受任何降脂治疗的患者、他汀类药物治疗有禁忌症的患者、甲状腺功能减退患者、低密度脂蛋白胆固醇>250mg/dL或血清甘油三酯>400mg/dL的患者以及正在服用调节细胞色素P450 3A4/5(CYP3A4/5)活性药物的患者被排除在研究之外。使用Naranjo药物不良反应概率量表标准对阿托伐他汀引起的AE进行因果关系评估,并使用Hartwig量表进行严重程度评估。与阿托伐他汀使用有因果关系的AE被报告为ADR。
在阿托伐他汀治疗的前45天内,145名(47.7%)患者中记录到183例AE。11%的患者AE可能归因于阿托伐他汀,89%的患者可能归因于阿托伐他汀。最常见的ADR是肌痛(41%),其次是神经系统ADR(35.5%)和胃肠道ADR(14%)。
肌痛是阿托伐他汀停药的最常见原因,这可能使这些个体心血管发病和死亡风险增加。应优先采取措施识别和处理阿托伐他汀引起的肌痛。